The Vaginal pH Modulator: A Revolutionary Approach to Contraception

The Vaginal pH Modulator: A Revolutionary Approach to Contraception

The Vaginal pH Modulator: A Revolutionary Approach to Contraception

Contraceptive options continue to expand. Find out how to counsel your patients based on efficacy, creeping Pearl Index, and sexual satisfaction.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Are you ready for the contraceptive revolution? Are you applying the latest information on contraceptive efficacy, recent clinical trial data, and sexual satisfaction when counseling your patients on contraceptive options? Join Dr. David Portman, Dr. David Eisenberg, and Ms. Patty Cason as they discuss the novel mechanisms of action of cutting-edge, non-hormonal contraceptive options, such as the vaginal pH modulator (VPM). Participating in this activity will ensure that you are prepared to discuss sexual and reproductive goals with your patients and confirm that your patients’ goals are being met.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    David J. Portman, MD
    Adjunct Instructor, OB-GYN, Ohio State University
    CEO & Chief Medical Officer
    Sermonix Pharmaceuticals
    Columbus, OH

    Employee of an ineligible company: Sermonix Pharmaceuticals
    Ownership Interest: Sermonix Pharmaceuticals
    Consulting Fees: Agile Therapeutics, Evofem Biosciences, Sebela Pharmaceuticals

    Patty Cason, RN, MS, FNP-BC
    President, Envision SRH
    Los Angeles, CA

    Consulting Fees: Organon, Sebela Pharmaceuticals

    David L. Eisenberg, MD, MPH, FACOG
    Associate Professor
    Department of Obstetrics & Gynecology
    Washington University in St. Louis School of Medicine
    St. Louis, MO

    Research: Evofem Biosciences, Medicines 360, Merck
    Ownership Interest: Femasys Inc.
    Consulting Fees: Evofem Biosciences, Femasys Inc., Medicines360, ACI Clinical/Sebela Pharmaceuticals

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Jay Runyon has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients considering contraception options. After participating in this educational activity, participants should be better able to:

    • Demonstrate competency in managing the contraception counseling process, including the ability to screen, assess, profile, and advise patients on appropriate contraceptive use
    • Explain the advantages and drawbacks of vaginal pH regulation contraception
    • Discuss the scientific data underlying the creeping Pearl Index demonstrated in contemporary clinical trials of contraception
    • Identify counseling strategies surrounding shared decision-making that will optimize patient contraceptive utilization, adherence, and satisfaction
  • Target Audience

    This activity is designed to meet the educational needs of ob-gyns, nurse practitioners, physician assistants, primary care physicians, pharmacists, and other members of the interprofessional team who are involved in the management of patients who are considering contraception options.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until February 14, 2023. PAs should claim only the credit commensurate with the extent of their participation.

    This curriculum has been approved for .25 contact hours (.025 CEUs ) by Global Learning Collaborative (GLC). GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN JA0006235-0000-22-001-H01-P. This learning activity is enduring based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Evofem Biosciences.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free